Science Corp Implants Vision-Restoration Chip in First Stargardt Disease Patient

Neuralink co-founder Max Hodak is back in the public eye. This time, his new company Science Corporation announced a major milestone on the TechCrunch Disrupt stage: its vision-restoration chip PRIMA has completed its first implantation in a Stargardt disease patient.

From Neuralink to Science Corporation: Hodak's New BCI Path

Max Hodak was formerly president and co-founder of Neuralink. After leaving, he founded Science Corporation. In his TechCrunch Disrupt talk, he detailed the company's work around PRIMA and how this path serves a larger goal — developing a new kind of brain-computer interface (BCI).

PRIMA is not a traditional invasive BCI. It is a retinal implant chip that restores vision by replacing the function of degenerated photoreceptors in the retina. Hodak frames this technology as an intermediate step toward broader BCI capabilities for Science Corporation, not the end goal.

This positioning is worth noting. The BCI field currently has multiple technological paths: Neuralink pursues a high-bandwidth invasive electrode array approach, while Synchron uses stent electrodes implanted via blood vessels. Science Corporation chose to start with the retina, seeking a balance between technical difficulty and clinical feasibility.

Differences in BCI technology paths: BCI today is broadly divided into invasive and non-invasive categories. Invasive approaches, represented by Neuralink, involve craniotomy to implant flexible electrode arrays directly into the cerebral cortex, enabling high-bandwidth neural signals but carrying high surgical risk and questionable long-term biocompatibility. Semi-invasive approaches like Synchron deliver stent electrodes through blood vessels to near the motor cortex, avoiding craniotomy but with limited signal quality. Non-invasive approaches collect EEG from the scalp — safe but low-resolution. Science Corporation's PRIMA is a retinal implant, strictly speaking a visual neuroprosthesis, sitting between invasive and non-invasive: it requires intraocular surgery but only acts on the retina, a peripheral neural tissue, with lower risk and complexity than cortical implantation. Hodak sees it as a springboard for accumulating electrode design, signal encoding, and clinical approval experience — not as a direct competitor in high-bandwidth BCI.

The PRIMA Chip and Stargardt Disease: Why This Indication

Stargardt disease is an inherited form of macular degeneration that causes progressive degeneration of photoreceptors in the central retina. Patients typically experience severe vision loss in young adulthood. It affects roughly one in 100,000 to one in 20,000 people worldwide.

Choosing Stargardt disease as the first clinical indication has its logic: patients' retinal ganglion cells and optic nerve pathways are usually still intact — the problem lies in the photoreceptor layer. PRIMA's role is precisely to bypass damaged photoreceptors and directly stimulate still-living neural cells with electrical signals.

This "replace rather than repair" approach has precedent in the retinal prosthesis field, such as Second Sight's Argus II. But PRIMA has made improvements in electrode density and signal processing, theoretically offering higher spatial resolution.

Pathological mechanisms of Stargardt disease: Stargardt disease is the most common inherited macular degeneration, mostly caused by ABCA4 gene mutations, inherited in an autosomal recessive pattern. This gene defect prevents retinal pigment epithelial cells from properly metabolizing retinoid derivatives, causing lipofuscin to accumulate within cells, which in turn leads to progressive apoptosis of photoreceptors (cones and rods) in the macular region. Patients typically develop symptoms between ages 10 and 20, with progressive decline in central vision, potentially leaving only peripheral vision. The key point: the disease mainly affects the photoreceptor layer, while downstream retinal ganglion cells and the optic nerve are often relatively preserved. This provides an intervention window for PRIMA — the chip bypasses non-functional photoreceptors and directly electrically stimulates ganglion cells, producing visual perception in the cerebral cortex.

What the First Implantation Means

The successful implantation of PRIMA in the first Stargardt patient is a critical milestone for Science Corporation, moving from animal experiments and engineering design into human clinical validation. Hodak did not disclose the patient's post-surgical vision recovery details in his talk, meaning it is still too early to assess PRIMA's actual efficacy.

From an industry perspective, the significance of this progress lies in the fact that the retinal prosthesis field had grown quiet after Argus II was discontinued. Science Corporation's advance has reinjected momentum into this direction. At the same time, it provides the BCI field with a reference sample different from Neuralink's highly invasive approach.

The real test lies in the clinical data to come. Successful implantation is only the first step. Whether the chip can work stably long-term, whether patients can achieve meaningful visual function improvement, and whether surgical risks are manageable — the answers to these questions will determine whether PRIMA can move toward commercialization.

History and challenges of retinal prostheses: Second Sight's Argus II was the first FDA-approved retinal prosthesis, launched in 2013. It captured images via a camera on glasses, converted them into electrical signals through an external processor, and wirelessly transmitted them to an intraocular electrode array to stimulate the retina. It helped some retinitis pigmentosa patients perceive light spots and motion, but resolution was extremely low, and it was discontinued in 2019 due to the company's financial difficulties. PRIMA significantly improves electrode density: it uses a photovoltaic principle, powered by an infrared projector on glasses that also transmits images. The chip is thinner with more pixels, theoretically offering higher spatial resolution. However, retinal prostheses generally face challenges including long-term stability, electrode corrosion, neural adaptation, and individual variability. Whether PRIMA can break through these bottlenecks still requires years of clinical follow-up validation.

Retinal Implants in the BCI Landscape

Hodak describes PRIMA as one of the paths toward a new kind of BCI — and that phrasing itself is worth pondering. The retina, as an extension of the central nervous system, is the front-end interface between the brain and the external world. Experience accumulated from the retina — electrode design, biocompatibility, signal encoding — can be transferred to the development of more complex cortical interfaces.

In other words, Science Corporation may be using PRIMA to validate a technology stack and clinical pathway, while the true long-term goal remains a broader brain-computer interface. This "laying eggs along the way" strategy has its pragmatic merits in both capital efficiency and regulatory approval.

The BCI industry is undergoing a transition from proof-of-concept to clinical deployment. Science Corporation's PRIMA progress adds a footnote to this transition from the retinal direction.

One-line Summary

Former Neuralink executive Hodak's new company completes first Stargardt retinal chip implant as an intermediate BCI step.

Paragraph Summary

Science Corporation announced at TechCrunch Disrupt that its vision-restoration chip PRIMA has completed its first implantation in a Stargardt disease patient. Founder Max Hodak, former Neuralink president and co-founder, positions PRIMA as an intermediate step toward broader brain-computer interfaces, not the end goal. Stargardt patients typically have intact retinal ganglion cells, and PRIMA restores vision by electrically stimulating to replace damaged photoreceptor function. The first successful implantation marks entry into human clinical validation, but long-term chip stability, degree of visual function improvement, and surgical risk control still await follow-up data. The progress reinvigorates the retinal prosthesis field and offers the BCI space a reference sample distinct from highly invasive approaches.